1. Home
  2. CYTK vs FSK Comparison

CYTK vs FSK Comparison

Compare CYTK & FSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CYTK
  • FSK
  • Stock Information
  • Founded
  • CYTK 1997
  • FSK 2007
  • Country
  • CYTK United States
  • FSK United States
  • Employees
  • CYTK N/A
  • FSK N/A
  • Industry
  • CYTK Biotechnology: Pharmaceutical Preparations
  • FSK Investment Managers
  • Sector
  • CYTK Health Care
  • FSK Finance
  • Exchange
  • CYTK Nasdaq
  • FSK Nasdaq
  • Market Cap
  • CYTK 5.6B
  • FSK 5.4B
  • IPO Year
  • CYTK 2004
  • FSK N/A
  • Fundamental
  • Price
  • CYTK $32.48
  • FSK $20.05
  • Analyst Decision
  • CYTK Buy
  • FSK Hold
  • Analyst Count
  • CYTK 19
  • FSK 6
  • Target Price
  • CYTK $77.33
  • FSK $20.08
  • AVG Volume (30 Days)
  • CYTK 2.4M
  • FSK 1.5M
  • Earning Date
  • CYTK 05-06-2025
  • FSK 05-07-2025
  • Dividend Yield
  • CYTK N/A
  • FSK 14.40%
  • EPS Growth
  • CYTK N/A
  • FSK N/A
  • EPS
  • CYTK N/A
  • FSK 1.90
  • Revenue
  • CYTK $19,218,000.00
  • FSK $1,687,000,000.00
  • Revenue This Year
  • CYTK $55.84
  • FSK N/A
  • Revenue Next Year
  • CYTK $646.96
  • FSK $0.31
  • P/E Ratio
  • CYTK N/A
  • FSK $10.24
  • Revenue Growth
  • CYTK 412.21
  • FSK N/A
  • 52 Week Low
  • CYTK $31.67
  • FSK $17.42
  • 52 Week High
  • CYTK $68.44
  • FSK $24.10
  • Technical
  • Relative Strength Index (RSI)
  • CYTK 31.23
  • FSK 51.29
  • Support Level
  • CYTK $34.88
  • FSK $19.33
  • Resistance Level
  • CYTK $43.51
  • FSK $20.01
  • Average True Range (ATR)
  • CYTK 2.00
  • FSK 0.40
  • MACD
  • CYTK -0.67
  • FSK 0.09
  • Stochastic Oscillator
  • CYTK 6.84
  • FSK 74.52

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

About FSK FS KKR Capital Corp.

FS KKR Capital Corp is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company. The company's investment objectives are to generate current income and, to a lesser extent, long-term capital appreciation. The company's portfolio is comprised of investments in senior secured loans and second lien secured loans of private middle market U.S. companies and, to a lesser extent, subordinated loans and certain asset-based financing loans of private U.S. companies.

Share on Social Networks: